# Nucleolus as a cornerstone linking proliferation and metabolism to cellular responses to stress: involvement of transcription factors MYC and p53

**Authors:** Аnastasiia Moraleva, Nadezhda Antipova, Pankrat Pavlov, Kira Dobrochaeva, Yury Rubtsov

PMC · DOI: 10.3389/fmolb.2026.1749992 · Frontiers in Molecular Biosciences · 2026-02-16

## TL;DR

This review explores how the nucleolus connects cell growth, metabolism, and stress responses, focusing on the roles of MYC and p53 in regulating ribosome production and disease.

## Contribution

The paper provides a comprehensive overview of the nucleolus's role in linking proliferation, metabolism, and stress responses through MYC and p53.

## Key findings

- The nucleolus regulates ribosome biogenesis and is central to cell cycle control and stress responses.
- Dysregulated ribosome biogenesis is linked to cancer and neurodegenerative diseases.
- MYC and p53 are key regulators of nucleolar activity and cellular responses to stress.

## Abstract

The nucleoli are a dynamic membraneless organelles in the nucleus playing a key role in cellular homeostasis. Transcription of rDNA, processing of rRNA, and assembly of the ribosomal subunits occur in nucleoli. Aside from ribosome biogenesis, the nucleolus is also involved in the regulation of other crucial functions, including DNA repair, regulation of cell cycle and apoptosis by mediating nucleolar stress responses. This makes it a key hub participating in regulation of various cellular processes. Given the fact, that protein biosynthesis is directly linked to multiple pathways and depends on ribosome production, it is not surprising that ribosome biogenesis is a centerpiece connecting fundamental cellular processes with each other. Of particular interest is the relationship between the nucleolus, cell cycle, and oncogenesis. In tumor and hyperproliferative cells, an increase in nucleolar size and activity directly correlates with enhanced ribosome biogenesis. This process is mutually controlled by oncogenes of the MYC family and tumor suppressors such as p53 and ARF. MYC plays a central role in regulating DNA transcription, and disrupting of ribosome biogenesis regulation could result in nucleolar stress. It induces activation of p53-dependent and p53-independent checkpoint pathways resulting in cell cycle arrest or apoptosis. In addition to its role in carcinogenesis, impaired ribosome biogenesis is associated with neurodegenerative diseases and ribosomopathies such as Diamond–Blackfan anemia. Thus, understanding the molecular mechanisms of nucleolar functions, and its links with main regulators of the cell cycle and oncogenesis is of great importance. It may help finding novel molecular targets and therapeutic approaches to treat disorders associated with dysregulated ribosome biogenesis and control of proliferation. This review considers the main aspects of nucleolar activity regulation, its role in the cell cycle and diseases, and the therapeutic prospects for targeting these processes.

## Linked entities

- **Genes:** MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609], TP53 (tumor protein p53) [NCBI Gene 7157], CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029]
- **Diseases:** Diamond–Blackfan anemia (MONDO:0015253)

## Full-text entities

- **Genes:** RICTOR (RPTOR independent companion of MTOR complex 2) [NCBI Gene 253260] {aka AVO3, PIA, hAVO3}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, MDM4 (MDM4 regulator of p53) [NCBI Gene 4194] {aka BMFS6, HDMX, MDMX, MRP1}, EBNA1BP2 (EBNA1 binding protein 2) [NCBI Gene 10969] {aka EBP2, NOBP, P40}, PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142] {aka ADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1}, RPL26 (ribosomal protein L26) [NCBI Gene 6154] {aka DBA11, L26, uL24}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}, COL18A1 (collagen type XVIII alpha 1 chain) [NCBI Gene 80781] {aka GLCC, KNO, KNO1, KS}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}, Mdm2 (MDM2 proto-oncogene) [NCBI Gene 17246] {aka 1700007J15Rik, Mdm-2}, MDM2 (MDM2 proto-oncogene) [NCBI Gene 4193] {aka ACTFS, HDMX, LSKB, hdm2}, GNL3 (G protein nucleolar 3) [NCBI Gene 26354] {aka C77032, E2IG3, NNP47, NS, Nug1}, Atr (ataxia telangiectasia and Rad3 related) [NCBI Gene 245000], HSPA4 (heat shock protein family A (Hsp70) member 4) [NCBI Gene 3308] {aka APG-2, HEL-S-5a, HS24/P52, HSPH2, RY, hsp70}, Rpl5 (ribosomal protein L5) [NCBI Gene 100503670] {aka Ska23, Ska<m23Jus>, Skax23, U21RNA}, RPS11 (ribosomal protein S11) [NCBI Gene 6205] {aka S11, uS17}, SNORD42A (small nucleolar RNA, C/D box 42A) [NCBI Gene 26809] {aka RNU42A, U42, U42A}, RPS6KB2 (ribosomal protein S6 kinase B2) [NCBI Gene 6199] {aka KLS, P70-beta, P70-beta-1, P70-beta-2, S6K-beta2, S6K2}, Mmp3 (matrix metallopeptidase 3) [NCBI Gene 17392] {aka EMS-2, MMP-3, SL-1, SLN-1, SLN1, STR-1}, Atm (ataxia telangiectasia mutated) [NCBI Gene 11920] {aka C030026E19Rik}, CDK2 (cyclin dependent kinase 2) [NCBI Gene 1017] {aka CDKN2, p33(CDK2)}, MYCN (MYCN proto-oncogene, bHLH transcription factor) [NCBI Gene 4613] {aka FGLDS1, MODED, MPAPA, MYCNsORF, MYCNsPEP, N-myc}, RPS14 (ribosomal protein S14) [NCBI Gene 6208] {aka EMTB, S14, uS11}, RPS23 (ribosomal protein S23) [NCBI Gene 6228] {aka BTDD, MABAS, MCINS, PAMAS, S23, uS12}, TSC2 (TSC complex subunit 2) [NCBI Gene 7249] {aka LAM, PPP1R160, TSC4}, Cdk2 (cyclin dependent kinase 2) [NCBI Gene 12566] {aka A630093N05Rik}, MYBBP1A (MYB binding protein 1a) [NCBI Gene 10514] {aka P160, PAP2, Pol5}, RPL5 (ribosomal protein L5) [NCBI Gene 6125] {aka L5, MSTP030, PPP1R135, uL18}, Surf6 (surfeit gene 6) [NCBI Gene 20935] {aka D2Wsu129e, Surf-6}, PES1 (pescadillo ribosomal biogenesis factor 1) [NCBI Gene 23481] {aka NOP7, PES}, RPS19 (ribosomal protein S19) [NCBI Gene 6223] {aka DBA, DBA1, LOH19CR1, S19, eS19}, EMG1 (EMG1 N1-specific pseudouridine methyltransferase) [NCBI Gene 10436] {aka C2F, Grcc2f, NEP1}, SLURP1 (secreted LY6/PLAUR domain containing 1) [NCBI Gene 57152] {aka ANUP, ARS, ArsB, LY6-MT, LY6LS, MDM}, GTF3C1 (general transcription factor IIIC subunit 1) [NCBI Gene 2975] {aka TFIIIC, TFIIIC220, TFIIICalpha}, FBL (fibrillarin rRNA 2'-O-methyltransferase) [NCBI Gene 2091] {aka FIB, FLRN, Nop1, RNU3IP1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, NUCLEOLIN (nucleolin multifunctional protein) [NCBI Gene 4691] {aka C23, NCL, Nsr1}, MUL1 (mitochondrial E3 ubiquitin protein ligase 1) [NCBI Gene 79594] {aka C1orf166, GIDE, MAPL, MULAN, RNF218}, RPS7 (ribosomal protein S7) [NCBI Gene 6201] {aka DBA8, S7, eS7}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, TRIM24 (tripartite motif containing 24) [NCBI Gene 8805] {aka PTC6, RNF82, TF1A, TIF1, TIF1A, TIF1ALPHA}, MAF1 (MAF1 negative regulator of RNA polymerase III) [NCBI Gene 84232], RPS20 (ribosomal protein S20) [NCBI Gene 6224] {aka S20, uS10}, RPL11 (ribosomal protein L11) [NCBI Gene 6135] {aka DBA7, GIG34, L11, uL5}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, RPSA (ribosomal protein SA) [NCBI Gene 3921] {aka 37LRP, 67LR, ICAS, LAMBR, LAMR1, LBP}, Eif4e (eukaryotic translation initiation factor 4E) [NCBI Gene 13684] {aka EG668879, Eif4e-ps, If4e, eIF-4E}, MRE11 (MRE11 double strand break repair nuclease) [NCBI Gene 4361] {aka ATLD, HNGS1, MRE11A, MRE11B}, IRS1 (insulin receptor substrate 1) [NCBI Gene 3667] {aka HIRS-1}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, MIR504 (microRNA 504) [NCBI Gene 574507] {aka MIRN504, hsa-mir-504, mir-504}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, drosha (drosha ribonuclease III) [NCBI Gene 567505] {aka im:7150667, rnasen, zgc:158612}, CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026] {aka CAP20, CDKN1, CIP1, MDA-6, P21, SDI1}, PIM1 (Pim-1 proto-oncogene, serine/threonine kinase) [NCBI Gene 5292] {aka PIM}, BDP1 (BDP1 general transcription factor IIIB subunit) [NCBI Gene 55814] {aka DFNB112, HSA238520, TAF3B1, TFC5, TFIIIB'', TFIIIB150}, DDX21 (DExD-box helicase 21) [NCBI Gene 9188] {aka GUA, GURDB, II/Gu, RH, RH II/Gu, RH-II/GU}
- **Diseases:** nervous system malformations (MESH:D009421), inflammation (MESH:D007249), neurodegeneration (MESH:D019636), hyperproliferative disease (MESH:D004194), ID (MESH:C537985), congenital ribosomopathies (MESH:D008209), Cancer (MESH:D009369), congenital dyskeratosis (MESH:C565079), Huntington (MESH:D006816), Alzheimer (MESH:D000544), nucleolar impairment (MESH:D060825), tissue failure (MESH:D051437), SDS (MESH:D000081003), ASD (MESH:D001321), BRCA-deficient tumors (OMIM:604370), X-DC (MESH:D019871), microcephaly (MESH:D008831), nervous system tumors (MESH:D009423), carcinogenesis (MESH:D063646), multisystemic ribosomopathy (MESH:D019578), BCS (MESH:C537081), proliferative (MESH:D009220), MDS (MESH:D009190), sarcomas (MESH:D012509), hematological malignancies (MESH:D019337), inherited disorders (MESH:D030342), AML (MESH:D015470), 5q syndrome (MESH:C535323), neuronal dysfunction and (MESH:D009461), hypoxia (MESH:D000860), flexion contractures of the joints (MESH:D003286), bone marrow failure (MESH:D000080983), dysplastic (MESH:D004416), ALS (MESH:D000690), metastasis (MESH:D009362), leukemia (MESH:D007938), colorectal cancer (MESH:D015179), death (MESH:D003643), intellectual disability (MESH:D008607), gastrointestinal and hematological toxicities (MESH:D006402), Treacher Collins syndrome (MESH:D008342), DBA (MESH:D029503), gynecologic tumors (MESH:D005833), CHH (MESH:C535916), tumor suppressor (OMIM:601308), micrognathia (MESH:D008844), cytotoxicity (MESH:D064420), Breast cancer (MESH:D001943), lymph node metastases (MESH:D008207), lymphoma (MESH:D008223), skeletal defects (MESH:C567306), nucleolar dysfunction (MESH:D006331), ovarian cancer (MESH:D010051), amino acid deficiency (MESH:D000592), oncological (MESH:D000072716), FTD (MESH:D057180), asplenia (MESH:D059446), glioblastoma (MESH:D005909)
- **Chemicals:** acridine (MESH:D000166), uridine (MESH:D014529), acids (MESH:D000143), CX-5461 (MESH:C557717), 5-fluorouracil (MESH:D005472), aspirin (MESH:D001241), S-adenosylmethionine (MESH:D012436), Idasanutlin (MESH:C586849), DTT (MESH:D004229), NAC (-), actinomycin D (MESH:D003609), Pseudouridines (MESH:D011560), R (MESH:D001120), glutamine (MESH:D005973), cytarabine (MESH:D003561), glutathione (MESH:D005978), Nutlin-3a (MESH:C482205), naphthyridine (MESH:D009287), BMH-21 (MESH:C000627087), folate (MESH:D005492), ROS (MESH:D017382)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Danio rerio (leopard danio, species) [taxon 7955], Saccharolobus solfataricus (species) [taxon 2287], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Drosophila melanogaster (fruit fly, species) [taxon 7227]
- **Mutations:** S6, serine/threonine
- **Cell lines:** MEF — Mus musculus (Mouse), Finite cell line (CVCL_9115), HCT116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), MCF7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), HT-29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950704/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950704/full.md

## References

340 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950704/full.md

---
Source: https://tomesphere.com/paper/PMC12950704